Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
For Celgene the unthinkable suddenly looks less improbable
Celgene stock falls 9%, suggesting that an activist campaign to derail its takeover by Bristol-Myers Squibb is reaching critical mass.
Boston and Edwards make a smart judgement
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Medtech news over the Christmas period
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
The FDA’s proposed changes to device regulation are thin on detail
The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require…
Seven drug pricing proposals that will happen and a couple that won’t
US President Donald Trump’s blueprint offers various proposals to reduce drug prices, some more ambitious than others.
Not so unified: Brexit means uncertainty for European patent law
Unitary patents are important for the biopharma sector, but might be even more crucial for medtech.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.